NCT04584255 - Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

July 1, 2025

Study Completion Date

July 17, 2029

Conditions

Stage I Breast CancerStage II Breast CancerStage III Breast CancerBreast CancerHER2-negative Breast CancerGermline BRCA1 Gene MutationGermline BRCA2 Gene MutationDeleterious PALB2 Gene Mutation

Interventions

DRUG

Niraparib

Predetermined dosage PO Daily

DRUG

Dostarlimab

Predetermined Dosage, IV,q3 weeks

Trial Locations (8)

21287

Johns Hopkins University, Baltimore

37232

Vanderbilt-Ingram Cancer Center, Nashville

55905

Mayo Clinic, Rochester

98109

University of Washington / Fred Hutchinson Cancer Center, Seattle

06520

Yale University Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston